Home LiteratureArticle Details
PMID: 8426124 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia.

The Journal of experimental medicine ·Vol. 177 ·No. 2 ·1993-02-01 ·Pages 547-50

Gérard C, Bruyns C, Marchant A, Abramowicz D, Vandenabeele P, Delvaux A, Fiers W, Goldman M, Velu T

Abstract

Because of its ability to efficiently inhibit in vitro cytokine production by activated macrophages, we hypothesized that interleukin (IL) 10 might be of particular interest in preventing endotoxin-induced toxicity. We therefore examined the effects of IL-10 administration before lipopolysaccharide (LPS) challenge in mice. A marked reduction in the amounts of LPS-induced tumor necrosis factor (TNF) release in the circulation was observed after IL-10 pretreatment at doses at low as 10 U. IL-10 also efficiently prevented the hypothermia generated by the injection of 100 micrograms LPS. Finally, pretreatment with a single injection of 1,000 U IL-10 completely prevented the mortality consecutive to the challenge with 500 micrograms LPS, a dose that was lethal in 50% of the control mice. We conclude that IL-10 inhibits in vivo TNF secretion and protects against the lethality of endotoxin in a murine model of septic shock.

MeSH Terms
Animals Base Sequence Endotoxins/toxicity Hypothermia/prevention & control Interleukin-10/pharmacology Lipopolysaccharides/toxicity Mice Mice, Inbred BALB C Molecular Sequence Data Oligodeoxyribonucleotides/chemistry Secretory Rate/drug effects Shock, Septic/prevention & control Tumor Necrosis Factor-alpha/metabolism
Chemicals
Endotoxins Lipopolysaccharides Oligodeoxyribonucleotides Tumor Necrosis Factor-alpha Interleukin-10
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Gérard C
Institut de Recherche Interdisciplinaire, Université Libre de Bruxelles, Belgium.
Bruyns C
Marchant A
Abramowicz D
Vandenabeele P
Delvaux A
Fiers W
Goldman M
Velu T
References (24)
24 references, click to expand
  1. IL-10 inhibits cytokine production by activated macrophages.
    J Immunol. 1991 Dec 1;147(11):3815-22 PMID: 1940369
  2. Septic shock: pathogenesis.
    Lancet. 1991 Sep 21;338(8769):732-6 PMID: 1679876
  3. Macrophage deactivation by interleukin 10.
    J Exp Med. 1991 Dec 1;174(6):1549-55 PMID: 1744584
  4. Differentiation factor/leukemia inhibitory factor protection against lethal endotoxemia in mice: synergistic effect with interleukin 1 and tumor necrosis factor.
    J Exp Med. 1992 Apr 1;175(4):1139-42 PMID: 1552284
  5. Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-alpha.
    J Immunol. 1992 Aug 1;149(3):918-24 PMID: 1378868
  6. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.
    Science. 1985 Aug 30;229(4716):869-71 PMID: 3895437
  7. The use of thin acrylamide gels for DNA sequencing.
    FEBS Lett. 1978 Mar 1;87(1):107-10 PMID: 631324
  8. Identification of a monoclonal antibody specific for a murine T3 polypeptide.
    Proc Natl Acad Sci U S A. 1987 Mar;84(5):1374-8 PMID: 2950524
  9. Tumor necrosis factor mediates endotoxic effects in mice.
    Infect Immun. 1987 Jul;55(7):1622-5 PMID: 3596805
  10. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.
    Nature. 1987 Dec 17-23;330(6149):662-4 PMID: 3317066
  11. Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene.
    Science. 1987 Dec 4;238(4832):1408-10 PMID: 3500513
  12. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.
    J Clin Invest. 1988 Apr;81(4):1162-72 PMID: 3258319
  13. Structure-function relationship of tumour necrosis factor and its mechanism of action.
    Ciba Found Symp. 1987;131:109-23 PMID: 3131072
  14. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits.
    J Clin Invest. 1988 Jun;81(6):1925-37 PMID: 3384955
  15. Retroviruses expressing different levels of the normal epidermal growth factor receptor: biological properties and new bioassay.
    J Cell Biochem. 1989 Feb;39(2):153-66 PMID: 2565908
  16. A role for interleukin 1 in the in vivo actions of tumor necrosis factor.
    Lymphokine Res. 1989 Fall;8(3):269-74 PMID: 2789321
  17. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI.
    Science. 1990 Jun 8;248(4960):1230-4 PMID: 2161559
  18. Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock.
    J Infect Dis. 1990 Aug;162(2):421-7 PMID: 2373872
  19. Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoadsorbent assay.
    J Immunol. 1990 Nov 1;145(9):2938-45 PMID: 2145365
  20. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock.
    Nature. 1990 Dec 6;348(6301):550-2 PMID: 2147233
  21. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits.
    FASEB J. 1991 Mar 1;5(3):338-43 PMID: 1825816
  22. A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice.
    J Exp Med. 1991 Apr 1;173(4):1029-32 PMID: 1826127
  23. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody.
    J Exp Med. 1991 Apr 1;173(4):931-9 PMID: 1826128
  24. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.
    J Exp Med. 1991 Nov 1;174(5):1209-20 PMID: 1940799
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
0022-1007
Published
1993-02-01
Pages
547-50
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC2190913
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com